Belgian drugmaker UCB (Euronext: UCB) and US biotech Amgen (Nasdaq: AMGN) have announced strong efficacy data from their Evenity (romosozumab) study, but a worrying safety signal caused shares in UCB to fall more than 10%.
The trial into Evenity, which is under co-development as a therapy for postmenopausal women with osteoporosis, met both primary endpoints and the key secondary endpoint.
However, a new safety signal was observed - a greater number of serious adverse events for the test group, 2.5% for romosozumab versus 1.9% for alendronate, at 12 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze